[HTML][HTML] Biomarkers for prostate cancer: prostate-specific antigen and beyond

MJ Duffy - Clinical Chemistry and Laboratory Medicine (CCLM), 2020 - degruyter.com
In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Prostate cancer screening and treatment: where have we come from and where are we going?

PC Albertsen - BJU international, 2020 - Wiley Online Library
Objective To evaluate the current prostate cancer screening and treatment paradigm in light
of recently published long‐term results of major screening and treatment trials. Methods …

Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for …

KE Hoffman, DF Penson, Z Zhao, LC Huang, R Conwill… - Jama, 2020 - jamanetwork.com
Importance Understanding adverse effects of contemporary treatment approaches for men
with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment …

Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)

TJ Wilt, TN Vo, L Langsetmo, P Dahm, T Wheeler… - European urology, 2020 - Elsevier
Background Very long-term mortality in men with early prostate cancer treated with surgery
versus observation is uncertain. Objective To determine long-term effects of surgery versus …

[HTML][HTML] 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during …

F Alongi, M Rigo, V Figlia, F Cuccia, N Giaj-Levra… - Radiation …, 2020 - Springer
Abstract Background Unity Elekta is a unique magnetic resonance (MR)-linac that
conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator. A prospective …

Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international …

AH Lebastchi, AK George, TJ Polascik, J Coleman… - European urology, 2020 - Elsevier
Background Focal therapy (FT) and partial gland ablation (PGA) are quickly adopted by
urologists and radiologists as an option for the management of localized prostate cancer …

[HTML][HTML] Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial …

DE Neal, C Metcalfe, JL Donovan, JA Lane, M Davis… - European urology, 2020 - Elsevier
Abstract Background The ProtecT trial reported intention-to-treat analysis of men with
localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical …

Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study

CG Mazariego, S Egger, MT King, I Juraskova, H Woo… - bmj, 2020 - bmj.com
Objective To assess treatment related changes in quality of life up to 15 years after
diagnosis of localised prostate cancer. Design Population based, prospective cohort study …

[HTML][HTML] Reconsidering the trade-offs of prostate cancer screening

JE Shoag, YA Nyame, R Gulati, R Etzioni… - The New England …, 2020 - ncbi.nlm.nih.gov
After the widespread adoption of prostate-specific antigen (PSA) screening in the early
1990s, prostate cancer diagnoses increased rapidly while death rates halved over the …

Patient-reported outcomes following treatment of localised prostate cancer and their association with regret about treatment choices

MA van Stam, NK Aaronson, JLHR Bosch… - European urology …, 2020 - Elsevier
Background Well-documented reports of patients' experiences with different treatments are
important for helping localised prostate cancer (LPC) patients choose among the available …